Dental whitening (bleaching) is contraindicated although it has been reported to lighten the color of DI teeth with some success; however, because the discoloration is caused primarily by the underlying yellow-brown dentin, this alone is unlikely to produce normal appearance in cases of significant discoloration.If there is considerable attrition, overdentures may be prescribed to prevent further attrition of remaining teeth and for preserving the occlusal face height. Management of DI associated with OI
Bisphosphonates have recently been introduced to treat several bone disorders, which include osteogenesis imperfecta.A recognized risk of this drug relevant to dental treatments is bisphosphonate-associated osteonecrosis of the jaw (BRONJ). Occurrences of this risk is associated with dental surgical procedures such as extractions. Dental professionals should therefore proceed with caution when carrying out any dental procedures in patients who have Type 2 DI who may be on bisphosphonate drug therapy. See also
Dentin
Dentinogenesis
Tooth development
Osteogenesis imperfecta

References

This article incorporates public domain text from The U.S. National Library of Medicine


== External links ==
Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names Giazo, Colazal in the US and Colazide in the UK. It is also sold in generic form in the US by several generic manufacturers. It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. It is in the category of disease-modifying antirheumatic drugs (DMARDs) family of medications. It is unclear exactly how it works. Synthesis
Ex 3 is actually for Ipsalazide. See Ex 4 for Balsalazide proper. Same protocol but uses β-Alanine. Starting material is 4-aminohippuric acid, obtained by coupling para-aminobenzoic acid and glycine. That product is then treated with nitrous acid to give the diazonium salt. Reaction of this species with salicylic acid proceeds at the position para to the phenol to give balsalazide. References
External links
"Balsalazide". Drug Information Portal. U.S. National Library of Medicine.